VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NOVT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
NOVTNovanta Inc.
$157.75$5.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksNOVTFinancials

Novanta Inc. (NOVT) Financials

28Y historyFree accessUpdated daily

Revenue growth remains lumpy due to OEM dependency, with quarterly growth fluctuating between 1.1% and 12.5% while gross margins have compressed to 41.8% as of 2026Q1.

NOVT Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98
Sales/Revenue1B980.6M949.25M881.66M860.9M706.79M590.62M626.1M614.34M521.29M384.76M373.6M364.71M341.61M271.5M366.28M383.52M254.39M288.47M291.08M313.61M260.78M330.01M185.56M159.07M247.9M373.86M274.6M144.2M
Revenue Growth %5.59%3.3%7.67%2.41%21.8%19.67%-5.67%1.91%17.85%35.49%2.99%2.44%6.76%25.82%-25.88%-4.49%50.76%-11.81%-0.9%-7.18%20.26%-20.98%77.85%16.65%-35.83%-33.69%36.15%90.43%-
Cost of Goods Sold588.13M572.79M527.7M481.76M482.43M406.46M346.11M364.01M352.81M300.76M222.31M215.71M214.54M202.16M157.02M205.9M217.12M156.44M190.85M177.95M183.45M156.91M196.57M117.08M109.88M167.26M239.44M167.7M96.6M
COGS % of Revenue-58.41%55.59%54.64%56.04%57.51%58.6%58.14%57.43%57.7%57.78%57.74%58.83%59.18%57.84%56.21%56.61%61.49%66.16%61.13%58.5%60.17%59.57%63.1%69.07%67.47%64.05%61.07%66.99%
Gross Profit416.81M407.81M421.55M399.9M378.47M300.33M244.52M262.08M261.53M220.53M162.45M157.89M150.17M139.45M114.48M160.38M166.4M97.95M97.62M113.13M130.16M103.87M133.44M68.48M49.19M80.64M134.42M106.9M47.6M
Gross Margin %41.48%41.59%44.41%45.36%43.96%42.49%41.4%41.86%42.57%42.3%42.22%42.26%41.17%40.82%42.16%43.79%43.39%38.51%33.84%38.87%41.5%39.83%40.43%36.9%30.93%32.53%35.95%38.93%33.01%
Gross Profit Growth %--3.26%5.41%5.66%26.02%22.82%-6.7%0.21%18.59%35.75%2.89%5.14%7.69%21.82%-28.62%-3.62%69.88%0.34%-13.71%-13.08%25.31%-22.16%94.87%39.2%-39%-40.01%25.74%124.58%-
Operating Expenses299.97M291.14M310.96M289.4M275.39M236.27M188.63M206.8M190.51M162.97M129.5M128.96M166.97M112.78M90.63M114.14M109.9M118.78M117.21M97.42M101.74M92.42M88.14M72.56M86.49M102.32M129.19M108.6M57.1M
OpEx % of Revenue-29.69%32.76%32.82%31.99%33.43%31.94%33.03%31.01%31.26%33.66%34.52%45.78%33.01%33.38%31.16%28.66%46.69%40.63%33.47%32.44%35.44%26.71%39.1%54.37%41.27%34.56%39.55%39.6%
Selling, General & Admin204.47M195.66M175.94M164.46M158.9M129.16M109.85M118.41M115.9M102.03M81.69M82.05M84.38M81.45M65.58M78.66M75.61M60.22M65.9M60.13M64.87M59.99M57.26M48.95M55.48M68.67M80.95M64.7M38.5M
SG&A % of Revenue-19.95%18.54%18.65%18.46%18.27%18.6%18.91%18.87%19.57%21.23%21.96%23.14%23.84%24.16%21.47%19.71%23.67%22.85%20.66%20.69%23.01%17.35%26.38%34.88%27.7%21.65%23.56%26.7%
Research & Development95.5M95.48M95.52M91.68M85.77M72.52M61M55.97M51.02M41.67M32M31.04M28.95M26.35M22.39M31.97M29.86M28.25M45.59M30.49M30.64M25.67M23.98M13.89M20.44M25.63M33.93M28.7M13M
R&D % of Revenue-9.74%10.06%10.4%9.96%10.26%10.33%8.94%8.31%7.99%8.32%8.31%7.94%7.71%8.25%8.73%7.79%11.11%15.8%10.47%9.77%9.84%7.26%7.49%12.85%10.34%9.08%10.45%9.02%
Other Operating Expenses0039.5M33.26M30.72M34.6M17.78M32.43M23.59M19.27M15.8M15.87M53.64M12.66M7.02M3.52M7.75M30.11M231.25M6.81M6.23M6.76M6.91M9.72M10.56M8.01M14.31M15.2M5.6M
Operating Income116.84M116.66M110.58M110.5M103.08M64.05M55.89M55.28M71.01M57.57M32.95M28.93M-16.81M19.45M15.01M43.94M53.91M-20.24M-245.13M22.65M28.42M11.45M45.29M-4.09M-37.3M-21.68M5.23M-1.7M-9.5M
Operating Margin %11.63%11.9%11.65%12.53%11.97%9.06%9.46%8.83%11.56%11.04%8.57%7.74%-4.61%5.69%5.53%12%14.06%-7.96%-84.98%7.78%9.06%4.39%13.73%-2.2%-23.45%-8.74%1.4%-0.62%-6.59%
Operating Income Growth %-5.5%0.08%7.2%60.93%14.61%1.1%-22.15%23.36%74.68%13.9%272.16%-186.42%29.58%-65.85%-18.49%366.39%91.74%-1182.43%-20.31%148.29%-74.73%1208.52%89.04%-72.06%-514.44%407.65%82.11%-
EBITDA179.37M178.6M166.15M157.11M156.24M107.45M94.18M93.56M108.06M88.32M53.31M48.05M6.99M39.65M27.46M59.21M69.56M-2.91M-226.22M37.11M43.27M25.16M58.91M6.35M-26.38M-9.76M19.54M13.5M-3.9M
EBITDA Margin %17.85%18.21%17.5%17.82%18.15%15.2%15.95%14.94%17.59%16.94%13.86%12.86%1.92%11.61%10.12%16.16%18.14%-1.14%-78.42%12.75%13.8%9.65%17.85%3.42%-16.58%-3.94%5.23%4.92%-2.7%
EBITDA Growth %4.81%7.49%5.75%0.56%45.41%14.09%0.66%-13.42%22.35%65.67%10.96%587.27%-82.37%44.38%-53.61%-14.89%2492.91%98.72%-709.61%-14.23%71.95%-57.29%827.31%124.09%-170.33%-149.94%44.73%446.15%-
D&A (Non-Cash Add-back)62.53M61.93M55.56M46.61M53.16M43.39M38.29M38.28M37.05M30.76M20.36M19.11M23.8M20.21M12.46M15.27M15.65M17.33M18.91M14.46M14.85M13.72M13.62M10.44M10.92M11.92M14.31M15.2M5.6M
EBIT116.84M116.66M124.29M123.31M107.46M82.07M59.7M71.86M79.05M65.11M40.9M37.19M26.57M24.83M14.32M38.25M39.35M-44.16M-241.43M22.3M28.53M11.9M46.26M-858K-31.87M-18.89M5.23M-1.7M-9.5M
Net Interest Income-17.67M-21.47M-31.49M-25.82M-15.62M-7.39M-6.56M-8.49M-9.81M-7.17M-4.56M-5.18M-5.1M-3.46M-2.79M-11.87M-19.82M-27.46M-7.08M6.51M3.81M1.65M717K000000
Interest Income00000000000000092K87K294K3.31M6.64M4.63M1.94M980K000000
Interest Expense17.67M21.47M31.49M25.82M15.62M7.39M6.56M8.49M9.81M7.17M4.56M5.18M5.1M3.46M2.79M11.96M19.91M27.75M10.39M128K821K291K263K000000
Other Income/Expense-47.26M-47.02M-31.52M-26.75M-15.92M-7.88M-7.49M-9.52M-9.71M18.57M-433K17.09M-1.11M-4.92M-3.47M-11.88M-43.81M-51.67M-6.75M-474K2.38M2.42M-308K2.24M590K-797K69.81M-35.7M-1.8M
Pretax Income69.58M69.64M79.07M83.75M87.16M56.17M48.4M45.77M61.3M76.13M32.52M46.02M-17.91M14.53M11.53M32.06M10.1M-71.91M-251.88M22.17M30.8M13.86M44.99M-1.85M-36.7M-22.47M75.04M-37.4M-11.3M
Pretax Margin %6.92%7.1%8.33%9.5%10.12%7.95%8.2%7.31%9.98%14.6%8.45%12.32%-4.91%4.25%4.25%8.75%2.63%-28.27%-87.32%7.62%9.82%5.32%13.63%-1%-23.07%-9.06%20.07%-13.62%-7.84%
Income Tax15.86M15.81M14.98M10.87M13.11M5.84M3.88M4.99M10.21M13.83M10.52M10.39M-1.01M5.68M-10.94M3.06M10.74M-773K-39.03M7.48M9.06M4.21M3.52M322K-8.98M-7.77M29.67M-2.6M-3.3M
Effective Tax Rate %22.79%22.71%18.94%12.98%15.04%10.4%8.02%10.91%16.65%18.16%32.34%22.58%5.62%39.09%-94.85%9.53%106.33%1.07%15.5%33.75%29.42%30.34%7.81%-17.42%24.47%34.59%39.53%6.95%29.2%
Net Income53.72M53.83M64.09M72.88M74.05M50.33M44.52M40.77M49.11M60.05M22M35.62M-24.25M7.31M19.54M28.97M-687K-71.33M-203.85M15.15M21.74M9.66M41.47M-2.17M-27.72M-14.7M45.38M-34.8M-8M
Net Margin %5.35%5.49%6.75%8.27%8.6%7.12%7.54%6.51%7.99%11.52%5.72%9.53%-6.65%2.14%7.2%7.91%-0.18%-28.04%-70.67%5.21%6.93%3.7%12.57%-1.17%-17.43%-5.93%12.14%-12.67%-5.55%
Net Income Growth %-23.93%-16.01%-12.06%-1.58%47.13%13.05%9.19%-16.97%-18.22%172.92%-38.22%246.85%-431.81%-62.59%-32.56%4317.32%99.04%65.01%-1445.08%-30.3%125.15%-76.71%2011.11%92.17%-88.62%-132.39%230.39%-335%-
Net Income (Continuing)53.72M53.83M64.09M72.88M74.05M50.33M44.52M40.77M51.09M62.31M22M35.63M-16.91M9.98M28.3M29M-639K-71.14M-212.85M14.69M21.74M9.66M41.47M-2.17M-27.72M-14.7M45.38M-34.8M-8M
Discontinued Operations00000000000-13K-7.33M-2.65M000060K467K000000000
Minority Interest00000000046.92M00429K419K397K357K329K281K220K0000000000
EPS (Diluted)1.311.471.772.022.061.411.251.151.431.130.631.02-0.700.210.580.86-0.03-3.91-14.181.051.530.692.94-0.16-2.04-1.093.39-3.43-0.70
EPS Growth %-29.59%-16.95%-12.38%-1.94%46.1%12.8%8.7%-19.58%26.55%79.37%-38.24%245.71%-433.33%-63.79%-32.56%2966.67%99.23%72.43%-1450.48%-31.37%121.74%-76.53%1937.5%92.16%-87.16%-132.15%198.83%-390%-
EPS (Basic)-1.471.782.032.081.421.271.161.461.140.631.03-0.700.210.580.87-0.03-3.91-14.181.081.560.693.03-0.16-2.04-1.093.57-3.43-0.70
Diluted Shares Outstanding41.16M36.7M36.12M36.03M35.91M35.78M35.65M35.55M35.47M35.28M34.91M34.83M34.35M34.4M33.94M33.59M23.7M15.92M14.37M14.21M14.08M13.95M14.04M13.61M13.55M13.45M13.33M10.15M11.39M
Basic Shares Outstanding40.42M36.59M35.95M35.84M35.65M35.4M35.14M35.03M34.91M34.82M34.69M34.58M34.35M34.07M33.77M33.48M23.7M15.92M14.37M14.12M13.97M13.85M13.71M13.61M13.55M13.45M12.73M10.15M11.39M
Dividend Payout Ratio-----------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Acquisition integration and margin volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Exhibits Cyclical Lumpy

According to the provided quarterly income statements, Novanta's revenue growth has fluctuated significantly, ranging from a low of 1.1% in 2025Q1 to a peak of 12.5% in 2024Q4, suggesting that the company's reliance on OEM partnerships creates inherent lumpiness in its top-line expansion trajectory.

The inconsistent growth profile appears to reflect the underlying volatility in semiconductor and industrial capital equipment spending, which often offsets the more stable medical procedure-driven demand. Investors should monitor whether the recent 10.4% growth in 2026Q1 represents a sustainable recovery or merely a timing-related anomaly in OEM order fulfillment.

Gross Margin Compression Warrants Caution

As reported in financial statements, Novanta's gross margin has experienced a noticeable contraction from a peak of 45.6% in 2023Q4 to 41.8% in 2026Q1, indicating potential pressure from rising input costs or a shift in the product mix toward lower-margin hardware components within its portfolio.

This downward trend in gross profitability suggests that the company may be struggling to pass through inflationary costs to its OEM customers effectively. If this margin erosion persists, it may indicate that the competitive moat surrounding its precision components is not as robust as previously assumed in pricing negotiations.

Operating Leverage Remains Constrained Overhead

Based on the company's reported figures, operating income has failed to scale proportionally with revenue, as evidenced by operating margins hovering consistently between 10.9% and 13.3% over the last ten quarters, despite significant top-line growth during the same period of observation.

The lack of meaningful operating leverage suggests that the company's aggressive acquisition strategy is resulting in persistent, duplicated overhead costs across its various brands. Management appears to be struggling to achieve the necessary economies of scale, which may continue to suppress bottom-line profitability until integration efforts are fully realized.

Stock-Based Compensation Distorts Earnings Quality

Analysis of the income statement reveals that net income has been highly volatile, dropping to as low as $4.5M in 2025Q2, a trend that appears heavily influenced by non-operating items and significant stock-based compensation expenses that frequently exceed $6M to $8M per quarter.

The disparity between operating income and net income suggests that shareholders should be wary of the quality of reported EPS, as non-cash charges and acquisition-related amortization appear to be masking the true underlying earnings power. Investors should focus on adjusted metrics to determine if the core business is generating sufficient cash to justify these recurring compensation costs.

Integration Risks Threaten Conglomerate Structure

While Novanta is often viewed as a medical technology enabler, the income statement data suggests a potential conglomerate discount, as the company's reliance on serial acquisitions creates a complex cost structure that may be masking underlying weakness in its core precision motion and photonics business segments.

Short-sellers might focus on the company's inability to expand operating margins despite its scale, which could indicate that the 'string-of-pearls' strategy is failing to produce the expected cross-selling synergies. If organic growth continues to decelerate, the market may begin to re-evaluate the company as a collection of disparate hardware businesses rather than a cohesive, high-growth medical technology platform.

NOVT — Frequently Asked Questions

Quick answers to the most common questions about buying NOVT stock.

What was Novanta Inc.'s (NOVT) revenue in 2025?

For fiscal year 2025, Novanta Inc. (NOVT) reported total revenue of $980.6M. This represents a 580.0% increase compared to $144.2M in 1998.

Is Novanta Inc. (NOVT) profitable?

Novanta Inc. (NOVT) is profitable, generating $53.8M in net income for the fiscal year ending 2025 with a net profit margin of 5.5%.

What is Novanta Inc.'s operating profit margin?

Novanta Inc. (NOVT) reported an operating income of $116.7M, resulting in an operating profit margin of 11.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Novanta Inc.'s gross profit and gross margin?

Novanta Inc. (NOVT) generated $407.8M in gross profit for the year, representing a gross profit margin of 41.6%. This demonstrates the company's core pricing power and production efficiency.